RDHL News and Press, Redhill Biopharma Ltd. From 01/28/23

3 Ways That Market Trends Impact Penny Stocks Performance Market trends can have a significant impact on the performance of penny stocks. Understanding these trends can help investors identify opportunities and make informed investment decisions. One way that market trends can impact pe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Connect world / Shutterstock.com GeneDx (NASDAQ: WGS ) stock is taking a beating on Friday after the company revealed a proposed public stock offering . According to a press release, GeneDx intends to rai...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market . ContraFect notes in a ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Akanda (NASDAQ: AKAN ) stock is on the rise Friday as the company’s shares continue a rally that started yesterday. That rally was kicked off by an update from the U.S. Food and Drug ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Friday after getting positive patent news from the U.S. Patent and Trademark Office (USPTO). The USPTO issue...

RedHill Biopharma ( NASDAQ: RDHL ) said that the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for a patent covering RHB-204's oral fixed-dose combination, methods treating pulmonary Mycobacterium avium Complex (MAC) disease. The patent will also cove...

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease PR Newswire Once issued, the patent is expected to extend protection of RHB-204 to 2041 RHB-204 is currently undergoing a Phase 3 study in the U.S. a...

Israel-based RedHill Biopharma ( NASDAQ: RDHL ) on Tuesday said results from its phase two study of its antiviral RHB-107 for the treatment of COVID-19 was published in the peer-reviewed International Journal of Infectious Diseases. U.S.-listed shares of the micro-cap specialty biopha...

RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19 PR Newswire Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed Internati...

NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL). About RedHill Biopharma Ltd. RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused o...